Eleanor’s Journey With KRAS+ Metastatic NSCLC

Opinion
Video

A 58-year-old retired teacher treated with adagrasib for KRAS+ metastatic NSCLC.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      This is an actor portrayal of a hypothetical patient profile developed for educational purposes based on characteristics of patients with KRAS+ non-small cell lung cancer as seen in clinical practice. The hypothetical case was co-developed by staff Medical Writers with Cancer Network/ONN.

      Recent Videos
      PERSEUS Trial: MRD Negativity
      PERSEUS Trial: MRD Negativity
      PERSEUS Trial: Design/Baseline Characteristics
      PERSEUS Trial: Design/Baseline Characteristics
      According to Jorge Nieva, MD, there are a multitude of things that can be explored to enhance the treatment landscape for lung cancer.
      Advances in NSCLC Bring Excitement in the Lung Space
      5 experts are featured in this series
      Expert Opinion on Modern Availability of Several Agents
      2 experts are featured in this series.
      CARTITUDE-1 Baseline Demographics
      5 experts are featured in this series
      Data Review of Teclistamab and Elranatamab in R/R MM
      2 experts are featured in this series.
      An Overview of CARTITUDE-1
      Taletrectinib showed improved efficacy in patients with ROS1-positive non–small cell lung cancer who were treatment-naïve.
      Taletrectinib Shows Positive Efficacy and Toxicity in ROS1+ NSCLC
      “It’s a drug that I’m very comfortable with, and it is a drug I’ll likely use primarily in the first-line setting,” stated Jorge Nieva, MD, on taletrectinib in non–small cell lung cancer.
      Taletrectinib is Suitable for First- and Second-Line ROS1+ NSCLC
      4 experts in this video
      Navigating CNS Disease in EGFR-Mutant NSCLC
      Related Content
      The Oncomine Dx Express Test may generate results in as little as 24 hours when used on the Ion Torrent Genexus Dx Integrated Sequencer.

      FDA OKs NGS Test for Tumor Profiling, as CDx for Sunvozertinib in NSCLC

      Roman Fabbricatore
      July 7th 2025
      Article

      The Oncomine Dx Express Test may generate results in as little as 24 hours when used on the Ion Torrent Genexus Dx Integrated Sequencer.

      Stephen Liu, MD, and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.

      Practice-Changing Lung Cancer Data From the 2025 ASCO Annual Meeting

      Stephen V. Liu, MD;Joshua K. Sabari, MD
      June 23rd 2025
      Podcast

      Stephen Liu, MD; and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.

      The MARIPOSA trial revealed promising survival benefits with amivantamab plus lazertinib vs osimertinib for patients with EGFR-mutant lung cancer.

      MARIPOSA OS Results Are Significant for EGFR+ NSCLC

      ONCOLOGY Staff
      July 2nd 2025
      Article

      The MARIPOSA trial revealed promising survival benefits with amivantamab plus lazertinib vs osimertinib for patients with EGFR-mutant lung cancer.

      Experts from Washington University in St. Louis discuss dosing considerations and toxicity management strategies for TROP2-targeted ADCs in NSCLC.

      Adopting Best Practices for Administering TROP2-Directed ADCs in NSCLC

      Daniel Morgensztern, MD;Mary Ellen Flanagan, NP ;Janelle Mann, PharmD, BCOP
      June 16th 2025
      Podcast

      Experts from Washington University in St Louis discuss dosing considerations and toxicity management strategies for TROP2-targeted ADCs in NSCLC.

      AI transforms non-small cell lung cancer management, enhancing diagnostics, treatment predictions, and personalized care strategies for improved patient outcomes.

      The Role of Artificial Intelligence in Enhancing Precision Medicine for NSCLC

      Puneet Modgil, MD
      June 24th 2025
      Article

      AI transforms non-small cell lung cancer management, enhancing diagnostics, treatment predictions, and personalized care strategies for improved patient outcomes.

      Developers plan to begin a rolling new drug application for zidesamtinib as a treatment for this non–small cell lung cancer population in July 2025.

      Zidesamtinib May Yield Meaningful Outcomes in Advanced ROS1+ NSCLC

      Russ Conroy
      June 24th 2025
      Article

      Developers plan to begin a rolling new drug application for zidesamtinib as a treatment for this non–small cell lung cancer population in July 2025.